ranbaxy pharma
TRANSCRIPT
-
8/8/2019 Ranbaxy Pharma
1/26
Ranbaxy Laboratories
LimitedTo become a Research based International
Pharmaceutical Company
Submitted By-:
Anand Kumar Singh S-03
Pankaj Kumar Jha S-13
Sandeep Kr Sharma S-20
Prabhat Kumar S-15
-
8/8/2019 Ranbaxy Pharma
2/26
INTRODUCTION
Type: Public (BSE: 500359) Industry :Pharmaceutical
Founded :1961
Headquarters: Gurgaon, Haryana, India
Products :Pharmaceuticals and diagnostics
Employees :1100 in R&D
Website: www.ranbaxy.com
-
8/8/2019 Ranbaxy Pharma
3/26
Company profile
Ranbaxy Laboratories Limited (Ranbaxy),India's largestpharmaceutical company.
Ranbaxy was started by Ranbir Singh and Gurbax Singh in1937
Ranbaxy was incorporated in 1961 and went public in1973.
Ranbaxy today has a presence in 23 of the top 25pharmaceutical markets of the world.
-
8/8/2019 Ranbaxy Pharma
4/26
Contd..
For the year 2009, the Company recorded GlobalSales of US $ 1519 Mn.
In 2009, North America, the Company's largest
market contributed sales of US $ 397 Mn, followedby Europe garnering US $ 269 Mn and Asiaclocking sales of around US $ 441 Mn.
In June 2008, Ranbaxy entered into an alliance
with one of the largest Japanese innovatorcompanies, Daiichi Sankyo Company Ltd.,
-
8/8/2019 Ranbaxy Pharma
5/26
Management team
Founder: Ranbir Singh and Gurbax Singh
Chairman : Dr. Tsutomu Une
M.D.+C.E.O. : Mr. Atul SobtiExpected C.E.O. :Malvinder Mohan Singh
President (R&d): Dr. Sudershan K. Arora
-
8/8/2019 Ranbaxy Pharma
6/26
Product profileValacyclovir
SimvastatinCo-Amoxyclav
Ciprofloxacin and Combinations
Amoxycillin and Combinations
Isotretinoin
Ketorolac Tromethamine
Loratadine and Combinations
Ginseng+Vitamins Cephalexin
Atorvastatin and Combinations
-
8/8/2019 Ranbaxy Pharma
7/26
The India Pharma Story Davos 2006
Source Financial Times
-
8/8/2019 Ranbaxy Pharma
8/26
India in Global Generics
% Share of USA DMF filings
India China
2004 27% 9%
2005 37% 10%
2006 44% 14%
Q406 47% 9%
Source: US FDA / J P Morgan Research
FDA Approved
Plants in India
Highest No
of DMF filings
-
8/8/2019 Ranbaxy Pharma
9/26
0
40
80
120
160
2002 2003 2004 2005
ANDA Filings in USA by Indian Companies
24
46
64
144
One in every four ANDAs filed by Indian Companies in top US FDA filers(Source: KPMG)
No Chinese generic company has yet filed a US FDA ANDA but expected
in 2008
India in Global Generics
-
8/8/2019 Ranbaxy Pharma
10/26
Ranbaxy Today
Amongst Top 10 Global Gx companies
Ground presence in 49 countries,
products sold in > 125
International business ~ 80% of sales
Manufacturing locations in 11 countries
> 11,000 employees, 51 nationalities
Strong Generics & Innovative researchcapabilities
2 0 0 1 2 0 0 3 2 0 0 6
$ 553
$ 972
$ 1339
CAGR
19%
Global Sales
Worldwide Presence
-
8/8/2019 Ranbaxy Pharma
11/26
-
8/8/2019 Ranbaxy Pharma
12/26
Increasing Focus on Costs
* Estimate, ^ Bio-Analytical / Bio - Equivalence
2005 2008*
Increasing sourcing from low costcountries .i.e. India & China
Improving R&D cost efficiencies
Optimizing SG&A cost structures
65% 80%35%20%
2006 2005
In-House 71% 28%
Overseas CRO 8% 61%
Indian CRO 21% 11%
% Bio-Studies (BA/BE^) conducted
2006 2005
Sales growth +17%
SGA growth - Nil
Advanced Markets Low Cost Countries
-
8/8/2019 Ranbaxy Pharma
13/26
Geographic Sales Split - 2006
Asia
$367, +19
A m er i cas
$440, +18
Europe$332, +23
Africa
$85, +24
* Including CIS, RoW Rest of the World
Global Sales 2006 (US$ Mn)
DF 1224 +20%
API 115 - 9%
Total 1339 + 17%
Sales 2006 Dosage Forms US$ 1224 Mn
Key New Markets Canada, Spain, Italy, Australia & Japan
33%
25%27%
6%
-
8/8/2019 Ranbaxy Pharma
14/26
Geographic Sales Split Q1 2007
Asia
$367, +19
Amer i ca
$440, +18
Europe$332, +23
Africa
$85, +24
* Including CIS, RoW Rest of the World
Global Sales Q1 2007 (US$ Mn)
DF 332 +30%
API 23 - 25%
Total 355 + 24%
Sales Q1 2007 Dosage Forms US$ 332 Mn
29%
31%27%
7%
-
8/8/2019 Ranbaxy Pharma
15/26
USA
Products pending approval
Source: Merrill Lynch Equity Research, February 2007
0
40
80
120
160
200
Teva Ranbaxy Sun Mylan Watson DRL Barr Par
#ofAND
As
Second largestpipeline
-
8/8/2019 Ranbaxy Pharma
16/26
Potential FTF Challenges
0
9
18
27
36
45
Teva
Ranb
axy
DRL
Mylan
Watson
Barr Pa
rSu
n
#ofFTFs
Second largestFTF pipeline
Source: Merrill Lynch Equity Research, February 2007
USA
-
8/8/2019 Ranbaxy Pharma
17/26
European Union
Presence in 23 of the 27 EU countries
Regulatory changes & price impacted
Western European markets
Strong product flow in 07 with
multiple Day 1s
Major countries
- Germany : AOK business
- France : Supplies from India
- UK : Gabapentin launch
RoE to maintain growth momentum
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
2 0 0 6 2 0 0 5
Sales
$ 267
$ 214
$ Mn
Romania
-
8/8/2019 Ranbaxy Pharma
18/26
India
Fastest growing Company in India on MAT basis
(Source :ORG-IMS Mat Mar 2007)
65 new products introduced in 2006
No 1 NDDS Company with 8% MS. Contribution to total sales ~ 9%
Dedicated task forces for Specialized & Chronic therapies
Chronic share contribution at 21% (2005 : 20%)
21 brands in Top 300 of Industry ( 2005 :19)
First to market 10
NDDS 6
In-licensed 8
Source : ORG IMS Audit Nov 2006, Moving Quarter Basis
GSK
Cipla
Ranbaxy
5.0%
4.9%
5.1%
Source : IMS - ORG
-
8/8/2019 Ranbaxy Pharma
19/26
Research & Development
New R&D facility for Drug
Discovery Research (DDR)
R&D I
R&D III
R&D II R&D IV
-
8/8/2019 Ranbaxy Pharma
20/26
Research & Development
Dedicated Facilities for Innovative & Generics Research
> 1400 R&D Personnel ( ~ 250 PhDs)
8 - 10 NCE molecules in pipeline
NDDS based products ( 4 platform technologies)R&D collaborations
Alliance /
Collaboration in
DDR
Out-licensing
in NDDS
Out-licensing
in DDR
-
8/8/2019 Ranbaxy Pharma
21/26
Ranbaxy GSK Collaboration
Expansion of strategic alliance established in 2003
Take leads beyond candidate selection to POC* in man
Therapeutic area focus of AI, Metabolic, Anti-inflammatory
and Oncology
> US$ 100 mn in milestone payments and double digit
royalties on commercialization of a product
Co- marketing rights in India
First candidate identified for Respiratory Inflammation
Proof of Concept
-
8/8/2019 Ranbaxy Pharma
22/26
Recent Acquisitions & Alliances
Terapia (Romania)
Be-Tabs (South Africa)
Allen (Italy)
Ethimed (Belgium)
Mundogen (Spain)
Zenotech (India)
Krebs (India)
Jupiter Biosciences*(Ind.)
Cardinal Drugs (India)
Auto-injector Tech.(USA)
* Subject to due diligence
http://images.google.co.in/imgres?imgurl=www.psconsortium.net/Images/alliances.jpg&imgrefurl=http://www.psconsortium.net/Alliances.html&h=200&w=320&prev=/images%3Fq%3Dalliances%2B%26start%3D40%26svnum%3D10%26hl%3Den%26lr%3D%26ie%3DUTF-8%26oe%3DUTF-8%26sa%3DN -
8/8/2019 Ranbaxy Pharma
23/26
Niche Alliances
Increasing focus on chronic / lifestyle diseases segment
High entry barriers - technology & resource intensive
Fermentation
based products
Bio-similars &
Oncologics
Peptides
KrebsZenotech Jupiter*
* Subject to due diligence
-
8/8/2019 Ranbaxy Pharma
24/26
Financials
Particulars
Sales
EBITDA
% sales
OPBT*
PBT
PAT
* 2005 sales excludes sales from discontinued operations .i.e Allied Businesses. OPBT Operating profit before tax
Figures in US$ Mn
Q1 2007 %
355 24%
43
12%
35%
36 102%
37 94%
29 81%
2006 %
1339 17%
207
16%
144%
131 481%
144
226%
114 90%
-
8/8/2019 Ranbaxy Pharma
25/26
In Summary
A strong 2006 performance on all parameters
Buoyant performance across key geographies
Continuing focus on cost optimization
Robust product flow
Growth through organic & inorganic
Discovery pipeline progressing well
Global Generic rank 9th / 10th
-
8/8/2019 Ranbaxy Pharma
26/26
Thank You